NPCE · NeuroPace Inc
$14.77
+0.09 (+0.61%)
At close · Jul 24
Market Cap
$504.93M
Shares
34.09M
NeuroPace Inc Earnings Call Transcripts
Every quarterly earnings call for NeuroPace Inc (NPCE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼19.2%
$10.20M
−$12.69M
'22 Q2
22-08-11
▲7.9%
$11.16M
−$11.79M
'22 Q3
22-11-08
▲16.3%
$12.79M
−$11.15M
'22 Q4
23-03-02
▲27.2%
$14.47M
−$10.38M
'23 Q1
23-05-04
▲61.9%
$16.51M
−$9.12M
'23 Q2
23-08-08
▲47.2%
$16.43M
−$7.26M
'23 Q3
23-11-06
▲40.8%
$18.01M
−$6.20M
'23 Q4
24-03-05
▲25.2%
$18.12M
−$8.93M
'24 Q1
24-05-08
▲16.6%
$19.26M
−$7.51M
'24 Q2
24-08-13
▲28.2%
$21.06M
−$5.45M
'24 Q3
24-11-12
▲19.2%
$21.47M
−$5.25M
'24 Q4
25-03-04
▲24.3%
$22.52M
−$6.59M
'25 Q1
25-05-13
▲22.1%
$23.52M
−$8.65M
'25 Q2
25-08-12
▲29.9%
$27.35M
−$3.50M
'25 Q3
25-11-04
▲23.9%
$26.59M
−$2.73M
'25 Q4
26-03-03
LATEST
▼2%
$22.07M
−$6.69M
'26 Q1
26-05-12
Earnings call
FY26 · Q1
2026-05-12
NeuroPace Inc Q1 FY2026 Earnings Call
Confident tone
Reimbursement landscape
IGE / NAUTILUS PMA supplement review
Commercial execution and prescriber growth
Revenue
$22.07M
▼ 2% YoY Diluted EPS
$-0.20
Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-14
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-11
Leerink Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-03
NeuroPace Inc Q4 FY2025 Earnings Call
Confident tone
Idiopathic generalized epilepsy (IGE) indication expansion
Profitability and cash generation
Core RNS business growth
Revenue
$26.59M*
▲ 23.9% YoY Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-14
44th Annual JP Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-04
NeuroPace Inc Q3 FY2025 Earnings Call
Confident tone
NAUTILUS IGE Indication and FDA
RNS Platform and Closed-Loop Technology
Project CARE and Market Expansion
Revenue
$27.35M
▲ 29.9% YoY Diluted EPS
$-0.11
Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-09-04
Cantor Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q2
2025-08-12
NeuroPace Inc Q2 FY2025 Earnings Call
Confident tone
Project CARE community expansion
NAUTILUS IGE pivotal trial and FDA submission
Revenue growth and record results
Revenue
$23.52M
▲ 22.1% YoY Diluted EPS
$-0.26
Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
NeuroPace Inc Q1 FY2025 Earnings Call
Confident tone
SEEG / DIXI Distribution Wind-Down
RNS Revenue Growth
Clinical Development Programs
Revenue
$22.52M
▲ 24.3% YoY Diluted EPS
$-0.21
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-04-08
24th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-03-10
Leerink Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-03-04
NeuroPace Inc Q4 FY2024 Earnings Call
Confident tone
Revenue growth and financial performance
Active prescribers and adoption in CECs
Nautilus idiopathic generalized epilepsy pivotal study
Revenue
$21.47M*
▲ 19.2% YoY Gross margin
75.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-01-15
43rd Annual JP Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-11-12
NeuroPace Inc Q3 FY2024 Earnings Call
Confident tone
Project CARE pilot and site of service expansion
Revenue growth and RNS System adoption
Gross margin and operating expense discipline
Revenue
$21.06M
▲ 28.2% YoY Diluted EPS
$-0.19
Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
NeuroPace Inc Q2 FY2024 Earnings Call
Positive tone
Revenue Growth and RNS Sales
Three-Phase Growth Strategy
Gross Margin Performance
Revenue
$19.26M
▲ 16.6% YoY Diluted EPS
$-0.26
Gross margin
73.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
NeuroPace Inc Q1 FY2024 Earnings Call
Confident tone
RNS System revenue growth and adoption
Total addressable market and long-term opportunity
DIXI Medical partnership
Revenue
$18.12M
▲ 25.2% YoY Diluted EPS
$-0.32
Gross margin
73.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
NeuroPace Inc Q4 FY2023 Earnings Call
Confident tone
RNS system revenue growth
DIXI Medical diagnostic electrodes partnership
Three-part growth strategy / modern RNS story
Revenue
$18.01M*
▲ 40.8% YoY Gross margin
75.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
NeuroPace Inc Q3 FY2023 Earnings Call
Revenue
$16.43M
▲ 47.2% YoY Diluted EPS
$-0.28
Gross margin
74.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
NeuroPace Inc Q2 FY2023 Earnings Call
Revenue
$16.51M
▲ 61.9% YoY Diluted EPS
$-0.36
Gross margin
72.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
NeuroPace Inc Q1 FY2023 Earnings Call
Revenue
$14.47M
▲ 27.2% YoY Diluted EPS
$-0.41
Gross margin
71.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
NeuroPace Inc Q4 FY2022 Earnings Call
Revenue
$12.79M*
▲ 16.3% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
NeuroPace Inc Q3 FY2022 Earnings Call
Revenue
$11.16M
▲ 7.9% YoY Diluted EPS
$-0.48
Gross margin
71.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
NeuroPace Inc Q2 FY2022 Earnings Call
Revenue
$10.20M
▼ 19.2% YoY Diluted EPS
$-0.52
Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
NeuroPace Inc Q1 FY2022 Earnings Call
Revenue
$11.37M
▲ 1.4% YoY Diluted EPS
$-0.47
Gross margin
72.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
NeuroPace Inc Q4 FY2021 Earnings Call
Revenue
$11.00M*
▲ 2.3% YoY Gross margin
73.4%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
NeuroPace Inc Q3 FY2021 Earnings Call
Revenue
$10.34M
▼ 19% YoY Diluted EPS
$-0.34
Gross margin
72.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
NeuroPace Inc Q2 FY2021 Earnings Call
Revenue
$12.63M
▲ 65.3% YoY Diluted EPS
$-0.48
Gross margin
74.1%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-06-03
NeuroPace Inc Q1 FY2021 Earnings Call
Revenue
$11.22M
▲ 12.5% YoY Diluted EPS
$-32.73
Gross margin
75.7%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–28 of 28 earnings calls